Bruker Corporation (BRKR) To Go Ex-Dividend on September 21st

Bruker Corporation (NASDAQ:BRKR) declared a quarterly dividend on Friday, August 14th. Shareholders of record on Monday, September 21st will be paid a dividend of 0.05 per share by the medical research company on Wednesday, October 7th. This represents a c) annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st.

Bruker has raised its dividend payment by an average of 0.0%per year over the last three years. Bruker has a dividend payout ratio of 7.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Bruker to earn $2.43 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 8.2%.

Bruker Trading Down 2.6%

Shares of BRKR stock traded down $1.66 on Friday, reaching $61.39. 2,820,290 shares of the company’s stock were exchanged, compared to its average volume of 2,108,620. Bruker has a 52 week low of $30.09 and a 52 week high of $65.30. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $9.35 billion, a PE ratio of -87.70, a P/E/G ratio of 1.93 and a beta of 1.26. The company’s fifty day simple moving average is $58.17 and its 200 day simple moving average is $49.90.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same quarter in the prior year, the company posted $0.32 EPS. Bruker’s quarterly revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts forecast that Bruker will post 2.12 EPS for the current year.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

Institutional investors have recently made changes to their positions in the business. Pallas Capital Advisors LLC acquired a new stake in Bruker in the second quarter worth about $570,746,000. Sculptor Capital LP boosted its position in Bruker by 9.0% in the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after purchasing an additional 270,000 shares in the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker in the 2nd quarter valued at $169,899,000. Dimensional Fund Advisors LP lifted its stake in shares of Bruker by 23.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock valued at $84,556,000 after purchasing an additional 448,440 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after buying an additional 1,756,460 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.